Nalin Qin

415 citations
11 papers · 335 indexed · h-index 7
Topics
MicroRNA in disease regulation (7 papers)Cancer-related molecular mechanisms research (5 papers)RNA modifications and cancer (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Nalin Qin

11 papers receiving 330 citations

Peers

Nalin Qin
Comparison fields: 5 of 55
  • Molecular Biology 230
  • Cancer Research 210
  • Immunology 87
  • Oncology 32
  • Pulmonary and Respiratory Medicine 24
Replace Christine Pich-Bavastro with:
Christine Pich-Bavastro Switzerland
Ross Wanner United States
Yingsheng Xiao China
Bowen Wang China
Mingqing Zhang China
Junyi Yin China
Yunping Luo China
Ana Inés Landoni Uruguay
Mark Owyong United States
G-J Zhang China
Nalin Qin relative to Christine Pich-Bavastro Switzerland Christine Pich-Bavastro's profile →
Citations per field
00.5×1.5×2.4×
Christine Pich-Bavastro · 1×
Citations per year

Countries citing papers authored by Nalin Qin

Since Specialization
Citations

This map shows the geographic impact of Nalin Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nalin Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nalin Qin more than expected).

Fields of papers citing papers by Nalin Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nalin Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nalin Qin. The network helps show where Nalin Qin may publish in the future.

Co-authorship network of co-authors of Nalin Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Nalin Qin. A scholar is included among the top collaborators of Nalin Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nalin Qin. Nalin Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
#WorkIndexed citations
1 2
2 47
3 39
4 90
5 31
6 32
7 2
8 4
9
[Over-expressed microRNA-7 inhibits the growth of human lung cancer cells via suppressing CGGBP1 expression].
6
10 24
11 58

About Nalin Qin

Nalin Qin is a scholar working on Cancer Research, Immunology and Molecular Biology, having authored 11 papers that have together received 335 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (7 papers), Cancer-related molecular mechanisms research (5 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Cancer Research (210 citations), Immunology (87 citations) and Molecular Biology (230 citations). Nalin Qin has collaborated with scholars based in China and United States. Frequent co-authors include Lin Xu, Juanjuan Zhao, Ya Zhou, Yijing Tao, Chao Chen, Mengmeng Guo, Dan Tian, Wen Zheng, Jing Zheng and Yijin Tao. Their work appears in journals such as Frontiers in Immunology, Journal of Leukocyte Biology and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026